Literature DB >> 16225632

Infliximab treatment for severe orogenital ulceration in Behçet's disease.

M Connolly, J S Armstrong, D A Buckley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16225632     DOI： 10.1111/j.1365-2133.2005.06914.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

1.  Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.

Authors:  Nádia Emi Aikawa; Carla Gonçalves; Clovis Artur Almeida Silva; Célio Gonçalves; Eloísa Bonfá; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2009-12-11       Impact factor: 2.631

2.  Behçet's disease, painful genital ulcerations and steroid pulse therapy.

Authors:  T Aldeen
Journal:  BMJ Case Rep       Date:  2009-02-27

Review 3.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

4.  Pulmonary aneurysms and intracardiac thrombi due to Behçet's disease in an African-American adolescent with oculocutaneous albinism.

Authors:  Lois M Endo; Steven M Rowe; Robb L Romp; Mark A Buckmaster; T Prescott Atkinson
Journal:  Clin Rheumatol       Date:  2006-09-19       Impact factor: 2.980

Review 5.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.